Department of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, P.R. China.
Department of Pathology, Affiliated Dongguan Hospital, Southern Medical University, (Dongguan People's Hospital), Guangzhou, P.R. China.
Clin Chem Lab Med. 2022 Jul 11;60(10):1577-1585. doi: 10.1515/cclm-2022-0338. Print 2022 Sep 27.
Patient-based real-time quality control (PBRTQC) has gained increasing attention in the field of laboratory quality management in recent years. However, PBRTQC has not been reported for use in molecular diagnostics. This study introduces PBRTQC to quantitative hepatitis B virus (HBV) DNA test using moving rate (MR) of positive and negative patient results.
In contrast to the MR protocols described in other literature, MR protocol for HBV-DNA test has an additional logarithmic transformation and binary conversion steps before using a common statistical process control algorithm, such as the MR. We used all patient test results of HBV-DNA assay from August 2018 to August 2021 at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, for parameters setting, optimization, and performance validation. The false rejection rate, error detection curves and validation charts were used to assess the MR protocols.
The false rejection rates of two MR protocols were both <0.7%. The optimal block sizes for positive and negative errors in each cut-off value were not the same, so we first proposed a combined protocol that used different block size to detect negative and positive errors. It turned out that the combined protocols outperformed the simple protocols for each cut-off value, especially detecting positive errors.
The performances of MR protocols using positive or negative patient results to detect constant errors of HBV-DNA test could meet laboratory requirements. Therefore, we have provided an effective alternative tool for internal quality control in the field of molecular diagnostics.
近年来,基于患者的实时质量控制(PBRTQC)在实验室质量管理领域受到越来越多的关注。然而,PBRTQC 尚未用于分子诊断。本研究通过阳性和阴性患者结果的移动率(MR)将 PBRTQC 引入定量乙型肝炎病毒(HBV)DNA 检测。
与其他文献中描述的 MR 方案不同,HBV-DNA 检测的 MR 方案在使用常见统计过程控制算法(如 MR)之前,有额外的对数转换和二进制转换步骤。我们使用 2018 年 8 月至 2021 年 8 月在广州中医药大学第二附属医院的所有 HBV-DNA 检测患者结果,用于参数设置、优化和性能验证。我们使用错误检出率、误差检测曲线和验证图来评估 MR 方案。
两种 MR 方案的错误拒受率均<0.7%。每个截止值的正负误差的最佳块大小不同,因此我们首次提出了一种使用不同块大小检测正负误差的组合方案。结果表明,组合方案在每个截止值下均优于简单方案,特别是检测阳性误差。
使用阳性或阴性患者结果来检测 HBV-DNA 检测恒定误差的 MR 方案的性能可以满足实验室要求。因此,我们为分子诊断领域的内部质量控制提供了一种有效的替代工具。